Screening and surveillance of Barrett's esophagus.
Esophageal adenocarcinoma (EAC) is the most rapidly increasing cancer in the Western world and Barrett's esophagus (BE) is the only known precursor lesion for this lethal cancer. Long-term survival may be improved if EAC is diagnosed early, providing an opportunity for early intervention. Screening for BE in patients with gastroesophageal reflux disease is not routinely recommended; however, if diagnosed, enrollment into a surveillance program may be beneficial. Surveillance of all patients with known BE is probably not cost-effective and factors predictive of BE progression to dysplasia/EAC are poorly understood. Screening and surveillance examinations are also faced with challenges in the endoscopic detection of intestinal metaplasia and dysplasia. Future application of molecular biomarkers may help identify the patients with BE most likely to progress, and the use of novel imaging methods may improve outcomes of BE screening and surveillance.
Michalak
Jeff
J
University of Kansas School of Medicine and Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Bansal
Ajay
A
Sharma
Prateek
P
D001471:Barrett Esophagus / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology; D018450:Disease Progression; D016099:Endoscopy, Gastrointestinal / Q000379:methods*; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D008403:Mass Screening / Q000379:methods*; D011159:Population Surveillance / Q000379:methods*; D011230:Precancerous Conditions; D015995:Prevalence; D014481:United States / Q000453:epidemiology